| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,489 |
1,245 |
$511K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,684 |
6,993 |
$367K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,491 |
3,030 |
$164K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,261 |
1,079 |
$113K |
| 87486 |
|
1,546 |
1,296 |
$71K |
| 87581 |
|
1,541 |
1,291 |
$70K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,170 |
3,465 |
$64K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,021 |
1,628 |
$47K |
| 99000 |
|
682 |
593 |
$16K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,182 |
806 |
$15K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
75 |
58 |
$11K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
137 |
112 |
$10K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
58 |
37 |
$10K |
| 0002A |
|
139 |
134 |
$6K |
| 0001A |
|
138 |
134 |
$6K |
| 0011A |
|
135 |
133 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
442 |
275 |
$5K |
| 0012A |
|
117 |
117 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
162 |
121 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
96 |
95 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
89 |
83 |
$2K |
| 81002 |
|
742 |
629 |
$2K |
| 96136 |
|
38 |
28 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
17 |
13 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
16 |
$734.76 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
17 |
12 |
$664.87 |
| 80053 |
Comprehensive metabolic panel |
59 |
58 |
$594.68 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
302 |
211 |
$449.93 |
| 84443 |
Thyroid stimulating hormone (TSH) |
28 |
28 |
$443.36 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
25 |
25 |
$429.80 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
53 |
39 |
$288.82 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
46 |
46 |
$264.04 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
102 |
74 |
$217.24 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
238 |
139 |
$203.39 |
| 99072 |
|
50 |
24 |
$175.00 |
| 36415 |
Collection of venous blood by venipuncture |
139 |
117 |
$12.90 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
277 |
184 |
$11.43 |
| 91301 |
|
118 |
117 |
$0.79 |
| 91300 |
|
75 |
63 |
$0.53 |